AU2012240945B2 - Macrophage activating factor for pharmaceutical compositions - Google Patents

Macrophage activating factor for pharmaceutical compositions Download PDF

Info

Publication number
AU2012240945B2
AU2012240945B2 AU2012240945A AU2012240945A AU2012240945B2 AU 2012240945 B2 AU2012240945 B2 AU 2012240945B2 AU 2012240945 A AU2012240945 A AU 2012240945A AU 2012240945 A AU2012240945 A AU 2012240945A AU 2012240945 B2 AU2012240945 B2 AU 2012240945B2
Authority
AU
Australia
Prior art keywords
protein
gcmaf
composition
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012240945A
Other languages
English (en)
Other versions
AU2012240945A1 (en
Inventor
Nobuto Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EFRANAT Ltd
Original Assignee
EFRANAT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46968677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012240945(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by EFRANAT Ltd filed Critical EFRANAT Ltd
Publication of AU2012240945A1 publication Critical patent/AU2012240945A1/en
Application granted granted Critical
Publication of AU2012240945B2 publication Critical patent/AU2012240945B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2012240945A 2011-04-07 2012-04-05 Macrophage activating factor for pharmaceutical compositions Ceased AU2012240945B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472642P 2011-04-07 2011-04-07
US61/472,642 2011-04-07
PCT/IL2012/000159 WO2012137199A1 (en) 2011-04-07 2012-04-05 Macrophage activating factor for pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2012240945A1 AU2012240945A1 (en) 2013-10-24
AU2012240945B2 true AU2012240945B2 (en) 2017-03-16

Family

ID=46968677

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012240945A Ceased AU2012240945B2 (en) 2011-04-07 2012-04-05 Macrophage activating factor for pharmaceutical compositions

Country Status (7)

Country Link
US (3) US20140030215A1 (enExample)
EP (1) EP2694088B1 (enExample)
JP (1) JP6113712B2 (enExample)
CN (1) CN103547280B (enExample)
AU (1) AU2012240945B2 (enExample)
CA (1) CA2832487A1 (enExample)
WO (1) WO2012137199A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2846861C1 (ru) * 2024-08-27 2025-09-17 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ одновременного определения уровня a-N-ацетилгалактозаминидазы (нагалазы) и антител к ней в иммуноферментной тест-системе

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105530950A (zh) * 2013-06-09 2016-04-27 艾弗兰纳特有限公司 包含Gc-巨噬细胞活化因子的组合物及其用途
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
WO2018025270A1 (en) * 2016-08-04 2018-02-08 Efranat Ltd. Enriched modified vitamin d binding protein compositions and use thereof
EP4260866A4 (en) * 2020-12-08 2025-01-01 Saisei Pharma Co., Ltd. MACROPHAGE ACTIVATOR

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326749A (en) * 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US6410269B1 (en) * 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5177002A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5177001A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5814225A (en) 1994-06-09 1998-09-29 Shanbrom Technologies Llc Iodinated gel filtration media for disinfecting protein solutions
US6096216A (en) 1994-06-09 2000-08-01 American National Red Cross Iodinated matrices for disinfecting biological fluids
EP1347953A2 (en) * 2000-11-09 2003-10-01 Northeastern Ohio Universities College of Medicine Agents and methods for promoting bone growth
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
EP2293065A3 (en) * 2002-07-03 2011-06-15 Illumigen Biosciences Inc. Methods and compositions for diagnosing hepatocellular carcinoma
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
WO2005077044A2 (en) * 2004-02-05 2005-08-25 ARIZONA BOARD OF REGENTS, acting for on behalf of ARIZONA STATE UNIVERSITY Rational design and engineering of proteins and peptides for immunomodulation
US20110123591A1 (en) 2009-08-22 2011-05-26 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326749A (en) * 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US6410269B1 (en) * 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAGASAWA H. et al., "Gc Protein (Vitamin D-binding Protein): Gc Genotyping and GcMAF Precursor Activity", Anticancer Research, 2005, Vol. 25, pages 3689-3696 *
YAMAMOTO N. et al., "Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF)", Journal of Medical Virology, January 2009, Vol. 81, No. 1, pages 16-26 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2846861C1 (ru) * 2024-08-27 2025-09-17 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ одновременного определения уровня a-N-ацетилгалактозаминидазы (нагалазы) и антител к ней в иммуноферментной тест-системе

Also Published As

Publication number Publication date
CA2832487A1 (en) 2012-10-11
US20170173115A1 (en) 2017-06-22
CN103547280B (zh) 2017-06-09
US20140030215A1 (en) 2014-01-30
AU2012240945A1 (en) 2013-10-24
EP2694088A1 (en) 2014-02-12
US20150361151A1 (en) 2015-12-17
EP2694088A4 (en) 2014-12-10
EP2694088B1 (en) 2017-06-07
WO2012137199A1 (en) 2012-10-11
JP2014511857A (ja) 2014-05-19
JP6113712B2 (ja) 2017-04-12
CN103547280A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
US12285462B2 (en) pH-triggered membrane peptide-mediated epitope tethering at cell surfaces
EP4059510B1 (en) Engineered extracellular vesicles and uses thereof
AU2018200381A1 (en) Modified polynucleotides
JP7505980B2 (ja) Ｃ３ｂ結合ポリペプチド
AU4393500A (en) Recombinant human mannan-binding lectin
US20170173115A1 (en) Macrophage activating factor for pharmaceutical compositions
BR112020004567A2 (pt) polipeptídeos para o tratamento de doenças
KR20180089446A (ko) 수지상 세포 조성물
EP0584558A2 (en) A composition for suppressing infection and growth of human immunodeficiency virus using an iron-binding protein
KR101535791B1 (ko) 개량형 이듀로네이트-2-설파타제 및 이의 용도
EP0546096B1 (en) Macrophage activating factor from vitamin d binding protein
EP0607186B1 (en) Macrophage activating factor from animal vitamin d-binding protein
CN102584976A (zh) 一种人血清淀粉样蛋白a1及其制备方法和应用
WO2024110757A1 (en) Control of nanocage self-assembly
US20250277223A1 (en) Methods of treating or preventing autoimmune diseases
HK1194290A (en) Macrophage activating factor for pharmaceutical compositions
NZ506695A (en) Utilization of cd137 in order to promote the profileration of peripheral monocytes
CN115989238A (zh) 包含il-2蛋白和cd80蛋白片段或其变体的融合蛋白及其用途
JPS60243018A (ja) ヒト内来性癌制御因子
AU2004316095A1 (en) Anticancer agent containing BL angiostatin
JP2002502257A (ja) グリコシル化腫瘍壊死因子の調製
JPH07238035A (ja) βアミロイド蛋白質分解剤
HK1041023A (en) Method for inducing cellular immunity and cells with induced cellular immunity
JP2015510887A (ja) 化膿性鼻副鼻腔炎の処置のためのチモシンαの使用
JP2007238605A (ja) 精製タンパク質の製造方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired